Article: Preliminary Results Show Improvement for Insomnia Patients with Co-Existing Depression Who Were Treated with Sepracor's Lunesta(TM).

Sepracor Inc. today announced the preliminary results of a Phase IIIB/IV, 545-patient, double-blind, placebo-controlled, ten-week study evaluating the efficacy and safety of LUNESTA(TM) brand eszopiclone in patients with insomnia and co-existing Major Depressive Disorder (MDD).

In this study, patients who met DSM-IV(1) criteria for both insomnia and MDD (either newly diagnosed or patients who have relapsed), were randomized to receive nightly PROZAC(R) brand fluoxetine and either eszopiclone 3 mg (n=270) or placebo (n=275) for the first eight weeks, followed by a two-week period in which patients discontinued eszopiclone treatment but continued receiving ...